• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Delcath Systems raises another $9.5m

August 20, 2019 By Nancy Crotti

Delcath Systemsdelcath-systems (OTC:DCTH) has closed on a $9.5 million private placement round, bringing the total amount raised since July to $29.5 million.

The Queensbury, N.Y.-based company priced the round at $1,000 per unit, with each unit consisting of a preferred convertible share worth 16,667 common shares, at a 6¢ strike price, and a five-year warrant for another share, also at 6¢ apiece.

Delcath developed the Chemostat hepatic delivery system, which is designed to isolate the liver’s circulatory system, infuse it with chemotherapy and then filter that blood before returning it to the patient.

“With this transaction completed, we have a cash runway beyond top-line data, a clean capitalization table and the foundation for a possible path to NASDAQ listing,” said Delcath president & CEO Jennifer K. Simpson in a news release. “Looking forward, we are positioned for success through multiple value inflection points including full enrollment, top-line data and NDA filing — targeted for Q4 2019, 1H 2020 and Q4 2020, respectively, in our registration trial for the treatment of metastatic Ocular Melanoma (mOM). mOM is a devastating disease of high unmet-need for which there is no approved standard-of-care in the United States and for which the Company has orphan drug designation.”

If it metastasizes, ocular melanoma usually moves first from the eye to the liver, as it is spread through the blood rather through than the lymphatic system, according to the Ocular Melanoma Foundation.

“The management team has laid the foundation for a leading interventional oncology platform company and now has the resources, capital structure and operational resources to move forward its long-term priorities and growth plans, to maximize shareholder value,” Simpson added.

Delcath also recently added John R. Sylvester, chief commercial officer of BTG, to its board of directors.

DCTH shares were up 32% to $0.126 in mid-morning trading.

Filed Under: Business/Financial News, Featured, Funding Roundup, Oncology, Uncategorized, Wall Street Beat Tagged With: BTG, Delcath Systems Inc.

IN CASE YOU MISSED IT

  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • Sequel Med Tech expects full twiist launch in the fall
  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS